25 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
7 Sep 23
Report of Foreign Private Issuer
7:25am
women and men, testifying that the drugs reversed their sexual dysfunction Properties: A3AR allosteric modulator Molecular weight – 411.34 Water insoluble
F-3
CANF
Can-Fite Biopharma Ltd
1 Sep 23
Shelf registration (foreign)
4:15pm
/ Motti Farbstein
Motti Farbstein
Chief Executive Officer and Chief Financial Offcier
POWER OF ATTORNEY
KNOW ALL MEN AND WOMEN BY THESE PRESENTED
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
14 Mar 22
Broad patent addresses markets for the treatment of all advanced liver fibrosis indications
7:19am
is the leading cause for liver transplants among women and second leading cause overall in the U.S. Given the rate of increase, it is expected to become
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
31 Jan 22
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
7:12am
% of the population. NASH is the leading cause for liver transplants among women and second leading cause overall in the U.S. Given the rate of increase
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
21 Oct 21
Report of Foreign Private Issuer
7:11am
among women and the second leading cause for liver transplants overall. NASH is expected to become the leading indication for liver transplants in males
6-K
EX-99.1
0n6lv3c1igagcj0ezn
2 Jun 21
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson
7:42am
424B4
757vb4e00wxw99m
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
dzwkel 3t
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
1tojm6a98knvgow0
24 Jan 20
Registration statement (foreign)
4:40pm
20-F/A
o6mlcc8mc1fxb45p 0f
2 Apr 19
Annual report (foreign) (amended)
6:52am
424B3
6wl v3gz38m9oh
22 Mar 19
Prospectus supplement
4:50pm
F-1/A
viqktz v3uby1y
12 Mar 19
Registration statement (foreign) (amended)
4:20pm
F-1
12ie y0ps
15 Feb 19
Registration statement (foreign)
4:32pm
424B3
8ltb0h0
24 Apr 14
Prospectus supplement
12:00am